Last reviewed · How we verify

Streptococcus Pneumoniae Chronic Bronchitis — Treatment Landscape & Competitive Intelligence

Streptococcus Pneumoniae Chronic Bronchitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Streptococcus Pneumoniae Chronic Bronchitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Zymar GATIFLOXACIN Allergan DNA gyrase, DNA gyrase, DNA gyrase subunit A 2003-01-01
Cefditoren Pivoxyl CEFDITOREN PIVOXIL Vansen Pharma Cephalosporin Antibacterial 2001-01-01
Avelox moxifloxacin Bayer AG Fluoroquinolone antibiotic (fourth-generation) DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A 1999-12-10
Cedax ceftibuten Burke Therap Cephalosporin Antibacterial 1995-01-01
Cefzil cefprozil Teva Pharmaceuticals USA Cephalosporin Antibacterial [EPC] 1991-01-01
Ceftin CEFUROXIME AXETIL GSK Cephalosporin Antibacterial 1987-01-01
Zinacef CEFUROXIME GSK Cephalosporin Antibacterial Carbonic anhydrase 2 1983-01-01
Azo Gantanol SULFAMETHOXAZOLE Pfizer Sulfonamide Antimicrobial [EPC] 1973-01-01
Trimethoprim TRIMETHOPRIM Dr Reddys Labs Sa Sulfonamide Antimicrobial [EPC] Dihydrofolate reductase 1973-01-01
Amoxil amoxicillin Generic (originally Beecham/GSK) Aminopenicillin (Beta-lactam antibiotic) 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C 1972-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 6 drugs in Streptococcus Pneumoniae Chronic Bronchitis
  2. GSK · 2 drugs in Streptococcus Pneumoniae Chronic Bronchitis
  3. Assistance Publique - Hôpitaux de Paris · 1 drug in Streptococcus Pneumoniae Chronic Bronchitis
  4. Bayer AG · 1 drug in Streptococcus Pneumoniae Chronic Bronchitis
  5. Bristol-Myers Squibb · 1 drug in Streptococcus Pneumoniae Chronic Bronchitis
  6. Burke Therap · 1 drug in Streptococcus Pneumoniae Chronic Bronchitis
  7. Dr Reddys Labs Sa · 1 drug in Streptococcus Pneumoniae Chronic Bronchitis
  8. Allergan · 1 drug in Streptococcus Pneumoniae Chronic Bronchitis
  9. Generic (originally Beecham/GSK) · 1 drug in Streptococcus Pneumoniae Chronic Bronchitis
  10. King George's Medical University · 1 drug in Streptococcus Pneumoniae Chronic Bronchitis
  11. Novartis Pharmaceuticals · 1 drug in Streptococcus Pneumoniae Chronic Bronchitis
  12. Pfizer · 1 drug in Streptococcus Pneumoniae Chronic Bronchitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Streptococcus Pneumoniae Chronic Bronchitis:

Cite this brief

Drug Landscape (2026). Streptococcus Pneumoniae Chronic Bronchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/streptococcus-pneumoniae-chronic-bronchitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing